Emmaus Life Sciences, Inc. · OTC:EMMA
Emmaus Life Sciences — Investor Presentation (August 2026)
27 slides from Emmaus Life Sciences's investor presentation, August 2026
Slide 1: Hope Delivered: Changing Lives For the Better
Hope Delivered: Changing Lives For the Better Discovering, developing, and commercializing innovative therapies to improve the quality of life for underserved patients and their communities Corporate Presentation | August 2026 Corporate Presentation | January 2023
Slide 2: Forward-looking statements
This presentation contains forward-looking statements regarding the research, development and commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or ch
Slide 3: Our Mission
Our Mission: Corporate|Presentation Corporate Presentation January 2023
Slide 4: Why invest in Emmaus?
A highly experienced management team with proven success in pharmaceutical research, development and commercialization working with solid supply chain and long term partners. Significant domestic and global opportunities targeting underserved sickle cell disease patient population and undeveloped th
Slide 5: Management team
Willis Lee, MS Chief Executive Officer and Chairman of the Board Charles Stark, Pharm.D. Chief Scientific Officer Hiroko Huynh, CPA Chief Accounting Officer Dale Short, JD Corporate Secretary Collective Experience Corporate Presentation | January 2023
Slide 6: Product pipeline
Product ID Preclinical Phase 1 Phase 2 Phase 3 Commercial Description ELS001 Pharmaceutical grade L-glutamine to treat SCD (Endari®) ELS004 Pharmaceutical grade L-glutamine to treat diverticulosis ELS003 Lab device/research tool to measure transmittance cell sheet ELS005 Cancer treatment targeting I
Slide 7: Cause and Effect
Cause and Effect Normal Sickled cells blood cells causing clumping Sickle cell disease (SCD) is an autosomal recessive disorder, meaning each parent carries one copy of mutated gene. Blood smear of a sickle cell disease patient The most prevalent symptom of SCD is pain. SCD affects an estimated 20M
Slide 8: Cause and Effect: NAD
Cause and Effect NAD is nicotinamide NAD exists in two forms: The higher levels of oxidants adenine dinucleotide, an oxidized and reduced form, experienced by SCD patients tilts a critical coenzyme found in abbreviated as the NAD+/NADH equilibrium every cell in your body, and towards NAD+ production
Slide 9: A domino effect
A domino effect Devastating mortality expectancy, reduced life expectancy Patients experience pain and acute symptoms with increasing severity Patients’ quality of as chronic damage accumulates. life suffers, as they endure excruciating The severe pain pain and subsequent experienced by SCD negative
Slide 10: A reduction in sickle cell crises extends lives
A reduction in sickle cell crises extends lives 44% p = 0.022 Endari® reduces instances of sickle cell crises Corporate Presentation | January 2023
Slide 11: Potential savings on treatment costs of over $2B annually (U.S.)
Potential savings on treatment costs of over $2B annually (U.S.)¹ Driving down SCD Breaking the SCD hospital hospitalization costs readmittance cycle 33% 41% 56% 59% 63% p = 0.005 p = 0.02 p = 0.02 p = 0.03 p = 0.003 Lower frequency Fewer days Delay in the onset of Delay in the onset of Fewer cases
Slide 12: Results for an early clinical trial patient after 12 weeks
The results for an Emmaus early clinical trial patient after 12 weeks of treatment Endari® E N D A R I ® C AU S E S P RO D U C T I O N O F N A D, WHICH “MOPS UP” OXIDANTS REDUCTION REDUCTION NAD+ + H+ + 2e- NADH NAD+ + H+ + 2e- NADH OXIDATION OXIDATION Corporate Presentation | January 2023
Slide 13: Endari vs. Siklos, Hydroxyurea, Adakveo
Siklos Endari® Hydroxyurea (Hydroxyurea) Adakveo (L-glutamine) (Amedica) Broad indication YES NO NO NO Black box warning NONE YES YES NONE Lab tests required NONE YES YES YES Patient age range 18+ years old, 5+ 2+ 16+ used off label years old years old years old for pediatrics Corporate Presentation
Slide 14: EMMA share structure
Ticker Symbol Shares Outstanding Fully Diluted Shares Insider Ownership EMMA 70,188,263 120,537,248 30%+ (OTCQB) (As of 6/30/2026) Corporate Presentation | January 2023
Slide 15: L-glutamine
No preliminary bloodwork or follow up testing needed High potential to be first L-glutamine choice medication for Can be delivered to telemedicine services is a key SCD a patient’s door and treatment that can taken at home be used alone or alongside other treatments Can be administered mixed into fo
Slide 16: 86% of patients reside in major metropolitan areas in 18 states
WA 86% of patients reside OR MT ND in major metropolitan ME MN ID NH SD WI areas in 18 states WY VT NY MA MI NV RI NE IA PA CT CA UT IL OH NJ CO IN DE WV MD KS VA MO KY AZ TN NC NM OK AR SC MS AL GA LA AK TX FL HI Corporate Presentation | January 2023
Slide 17: Global market opportunity: U.S., Europe, MENA, Latin America
Europe Focus on early access programs $480M EMA and UK approval process U.S. and EU Middle East & North Africa (MENA) Distribution partners in place Opened Dubai office in 2020 $3.4B Received approvals from UAE, Oman, Kuwait, Bahrain, Qatar Imminent approval from Saudi Arabia Rest of Wor
Slide 18: $30K annual wholesale acquisition cost per adult patient
$30K annual wholesale acquisition cost per adult patient Expand Network of over 600 pharmacies and growing Support Big 3 distributors: AmerisourceBergen, Cardinal Involvement with local and and McKesson national SCD foundations RXs filled in 44 states, Puerto Excellent payer coverage Rico and Washin
Slide 19: Current, pending and in-process approvals
Current Approvals United States FDA Israeli Ministry of Health United Arab Emirates Kuwait Qatar Bahrain Oman Puerto Rico Pending Approvals Kingdom of Saudi Arabia – One hospital with 24K SCD patients In process Early Access program in the U.K., France, Saudi Arabia, and Turkey SCD affects an estima
Slide 20: Growth Opportunities: Pancreatic Cancer Treatment
Growth Opportunities: Pancreatic Cancer Treatment Corporate Presentation | January 2023
Slide 21: Pancreatic Cancer Prevalence
Pancreatic Cancer Prevalence • US alone has 60K cases. The cases spread around developed countries. Pancreatic Cancer Cases (2022) (in K) 119 9.8 140 12.0 9.4 8.6 8.7 8.0 120 7.8 7.7 10.0 7.5 7.5 7.5 6.7 6.7 100 8.0 60 4.7 80 4.4 48 6.0 60 22 22 4.0 16 16 15 14 11 40 20 9 9 9 7 6 2.0 1.0 0 0.0 Cases
Slide 22: Base fact / assumption
Base fact / assumption • Cell lines of pancreatic cancer developed a survival skill by mutating KRAS protein, in a low glutamine condition. • Those cells grow faster in a low glutamine environment, but they die (or grow much slower) in the presence of glutamine. • By applying L-glutamine in addition
Slide 23: L-glutamine in pancreatic cancer
In the U.S., there are: Nearly 80% of PDAC patients ~67,000 will develop cachexia, marked by weight loss and muscle wasting, accounting for 80% new cases per year of cancer deaths. ~80% of new diagnoses Of those with advanced disease, the 5-year survival is are stage 3 or 4 a dismal 3%. L-glutamine
Slide 24: Promising Early Results
Promising Early Results The combination of Endari and Gemcitabine + Abraxane nearly tripled the overall survival and doubled the ORR compared to historical Gemcitabine + Abraxane alone Phase I Results Historical Controls Outcome Endari + Gemcitabine + Abraxane Gemcitabine + Abraxane Median OS 22 mon
Slide 25: Our engagement
Our engagement • Exclusive Agreement Executed: Signed an exclusive option agreement with a Top-tier US academic medical center (ranked among the best in the nation) in Dec 2025 • Capital Efficient Structure: Gained an 18-month exclusive window to secure external funding before full license execution
Slide 26: Investment highlights
Commercial stage company marketing Endari® – a safe and efficacious therapy for sickle cell disease Targeting large addressable markets in underserved patient populations Experiencing year-over-year revenue growth Investment highlights Clinical pipeline with multiple shots on goal Experienced leader
Slide 27: Emmaus Life Sciences, Inc. Investor Relations
Company: Emmaus Life Sciences, Inc. Investor Relations (310) 214-0065 IR@emmauslifesciences.com Corporate Presentation August 2026 Corporate Presentation | January 2023
Emmaus Life Sciences — Investor Presentation (August 2026) on 6ix